We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+4.35%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$7.24B
AUM Growth
+$171M
Cap. Flow
+$215M
Cap. Flow %
2.98%
Top 10 Hldgs %
34.84%
Holding
226
New
18
Increased
74
Reduced
41
Closed
9

Top Buys

Rank Stock Value
1
RLAY icon
Relay Therapeutics
RLAY
+$49.6M
2
EXAS
Exact Sciences
EXAS
+$26.3M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$25.9M
4
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$24.6M
5
MTEM
Molecular Templates, Inc.
MTEM
+$18.3M

Top Sells

Rank Stock Value
1
HALO icon
Halozyme
HALO
+$35.1M
2
PACB icon
Pacific Biosciences
PACB
+$25.7M
3
EVH icon
Evolent Health
EVH
+$20.6M
4
AKCA
Akcea Therapeutics Inc
AKCA
+$15.9M
5
MDT icon
Medtronic
MDT
+$14.7M

Sector Composition

Rank Sector Weight
1 Healthcare 95.98%
2 Industrials 0.6%
3 Technology 0.53%
4 Communication Services 0.41%
5 Financials 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRL icon
26
Charles River Laboratories
CRL
$10.5B
$79.5M 1.1%
351,083
-14,750
-4% -$3.06M
CRSP icon
27
CRISPR Therapeutics
CRSP
$4.67B
$79.4M 1.1%
949,262
+148,800
+19% +$13.2M
EXEL icon
28
Exelixis
EXEL
$14.2B
$75.1M 1.04%
3,073,500
+26,000
+0.9% +$607K
BSX icon
29
Boston Scientific
BSX
$65.3B
$72.1M 1%
1,886,297
+155,677
+9% +$6M
MYOV
30
DELISTED
Myovant Sciences Ltd.
MYOV
$71.5M 0.99%
5,092,000
+445,000
+10% +$8.28M
SYK icon
31
Stryker
SYK
$123B
$67.3M 0.93%
322,771
-1,171
-0.4% -$228K
EW icon
32
Edwards Lifesciences
EW
$49.2B
$66.1M 0.91%
827,818
+36,136
+5% +$2.82M
PODD icon
33
Insulet
PODD
$11.3B
$63.9M 0.88%
269,875
+38,126
+16% +$8.03M
BDX icon
34
Becton Dickinson
BDX
$42.7B
$60.7M 0.84%
267,367
+15,278
+6% +$3.75M
CNC icon
35
Centene
CNC
$32.8B
$60.3M 0.83%
1,033,647
-9,100
-0.9% -$565K
NKTR icon
36
Nektar Therapeutics
NKTR
$2.23B
$60.3M 0.83%
242,157
+6,489
+3% +$2.04M
GBIO
37
DELISTED
Generation Bio
GBIO
$58.1M 0.8%
188,000
+44,000
+31% +$10.5M
CI icon
38
Cigna
CI
$75.3B
$56.9M 0.79%
335,737
-989
-0.3% -$174K
RLAY icon
39
Relay Therapeutics
RLAY
$4.24B
$55.4M 0.77%
+1,300,000
New +$49.6M
MTEM
40
DELISTED
Molecular Templates, Inc.
MTEM
$54.8M 0.76%
334,800
+102,984
+44% +$18.3M
GWPH
41
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$54.8M 0.76%
562,943
+213,377
+61% +$24.6M
JAZZ icon
42
Jazz Pharmaceuticals
JAZZ
$15.5B
$50.8M 0.7%
356,350
+65,214
+22% +$8.08M
SRRK icon
43
Scholar Rock
SRRK
$6.24B
$50.3M 0.69%
2,842,515
+96,409
+4% +$1.43M
DXCM icon
44
DexCom
DXCM
$29.5B
$50.2M 0.69%
486,820
+76,000
+18% +$7.94M
HRC
45
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
$47.7M 0.66%
571,069
+149,775
+36% +$14.7M
HOLX
46
DELISTED
Hologic
HOLX
$46.3M 0.64%
696,980
+165,891
+31% +$10.5M
AMGN icon
47
Amgen
AMGN
$198B
$45.7M 0.63%
179,613
+11,650
+7% +$2.89M
HCA icon
48
HCA Healthcare
HCA
$82.1B
$43M 0.59%
345,085
+1,919
+0.6% +$238K
BDTX icon
49
Black Diamond Therapeutics
BDTX
$102M
$42.4M 0.59%
1,403,000
– –
CDNA icon
50
CareDx
CDNA
$1.98B
$42.3M 0.59%
1,115,903
-50,936
-4% -$1.72M
1
2
3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2020 Portfolio in Review

As of Q3 2020, Bellevue Group held 226 positions worth $7.24B, up 2.4% from $7.07B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Bellevue Group's Q3 2020 filing shows 18 new, 74 increased, 41 reduced and 9 closed positions. Its largest new stake was Relay Therapeutics: 1,300,000 shares worth $55.4M. The largest sale was Halozyme, an estimated $35.1M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q3 2020 buy was Relay Therapeutics: 1,300,000 shares worth $55.4M.
  • Bellevue Group added most to Ionis Pharmaceuticals in Q3 2020, an estimated $25.9M increase.
  • Bellevue Group's biggest Q3 2020 reduction was Halozyme, cutting an estimated $35.1M.
  • Bellevue Group fully exited BioMarin Pharmaceuticals in Q3 2020, selling an estimated $9.48M.
  • Bellevue Group's ten largest holdings make up 35% of its $7.24B portfolio in Q3 2020.
  • Bellevue Group opened 18 new positions and closed 9 in Q3 2020.
  • Bellevue Group's portfolio value rose 2.4% quarter-over-quarter to $7.24B.

Based on Bellevue Group's 13F filing for Q3 2020, filed 16 Nov 2020.